• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Cordran SP (flurandrenolide) Cream and Cordran Ointment

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – June 2013

Summary View

 

ADVERSE REACTIONS

Postmarketing Adverse Reactions
  • The following adverse reactions have been identified during post approval use of flurandrenolide, USP. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
  • Skin: skin striae, hypersensitivity, skin atrophy, contact dermatitis and skin discoloration